Kevin D. Bunker - Apr 11, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Operating Officer
Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Kevin D. Bunker
Stock symbol
ZNTL
Transactions as of
Apr 11, 2022
Transactions value $
-$152,745
Form type
4
Date filed
4/13/2022, 05:53 PM
Previous filing
Mar 21, 2022
Next filing
Jul 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$140K -4.6K -3.29% $30.37 135K Apr 11, 2022 See Footnote F1, F2, F3
transaction ZNTL Common Stock Sale -$9.72K -300 -0.22% $32.40 135K Apr 11, 2022 See Footnote F1, F3, F4
transaction ZNTL Common Stock Sale -$3.32K -100 -0.07% $33.16 135K Apr 11, 2022 See Footnote F1, F3
holding ZNTL Common Stock 764K Apr 11, 2022 Direct
holding ZNTL Common Stock 350 Apr 11, 2022 As UTMA custodian for sons
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.02 to $30.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.00 to $32.84. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.